Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITRM OTCMKTS:PXSLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITRMIterum Therapeutics$0.03$0.10$0.03▼$1.42$1.60M2.964.85 million shsN/APXSLYPharmaxis$0.88$0.88$0.62▼$1.47$26.53M1.221,000 shsN/ADon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITRMIterum Therapeutics0.00%0.00%0.00%-89.48%-96.99%PXSLYPharmaxis0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITRMIterum Therapeutics$0.03$0.10$0.03▼$1.42$1.60M2.964.85 million shsN/APXSLYPharmaxis$0.88$0.88$0.62▼$1.47$26.53M1.221,000 shsN/ADon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITRMIterum Therapeutics0.00%0.00%0.00%-89.48%-96.99%PXSLYPharmaxis0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITRMIterum Therapeutics 1.67Reduce$9.0029,900.00% UpsidePXSLYPharmaxis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PXSLY and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/30/2026ITRMIterum Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold3/4/2026ITRMIterum Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITRMIterum Therapeutics$390K4.10N/AN/A($0.15) per share-0.20PXSLYPharmaxis$8.75M3.03N/AN/A$0.04 per share22.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITRMIterum Therapeutics-$24.77M-$0.75N/AN/AN/AN/AN/A-65.54%5/20/2026 (Estimated)PXSLYPharmaxis-$9.36MN/AN/AN/AN/AN/AN/AN/AN/ALatest PXSLY and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2025ITRMIterum Therapeutics-$0.10N/AN/AN/A$1.40 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthITRMIterum TherapeuticsN/AN/AN/AN/AN/APXSLYPharmaxisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITRMIterum TherapeuticsN/A2.131.96PXSLYPharmaxis2.823.312.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITRMIterum Therapeutics9.21%PXSLYPharmaxisN/AInsider OwnershipCompanyInsider OwnershipITRMIterum Therapeutics2.00%PXSLYPharmaxisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITRMIterum Therapeutics1053.29 million52.23 millionNot OptionablePXSLYPharmaxis6930.15 millionN/ANot OptionablePXSLY and ITRM HeadlinesRecent News About These CompaniesSyntara Receives FDA Guidance on Amsulostat Development for MyelofibrosisAugust 10, 2025 | tipranks.comSyntara’s Amsulostat Receives WHO INN Recognition, Boosting Myelofibrosis Treatment ProspectsJuly 7, 2025 | tipranks.comSyntara’s SNT-5505 Receives FDA Fast Track Designation for Myelofibrosis TreatmentJune 9, 2025 | tipranks.comPharmaxis Ltd Highlights Uncertainties in Syntara’s Future ProjectionsMay 6, 2025 | tipranks.comPharmaxis Ltd March Quarter Shareholder UpdateApril 30, 2025 | tipranks.comSyntara’s SNT-6302 Shows Promising Results in Scar Treatment TrialFebruary 17, 2025 | tipranks.comPharmaxis Ltd General Meeting Addresses Key ResolutionsFebruary 16, 2025 | tipranks.comPharmaxis Ltd Reveals Interim Results at Hematology ForumFebruary 3, 2025 | tipranks.comSyntara Reports Promising Interim Results for Myelofibrosis TreatmentJanuary 28, 2025 | tipranks.comPharmaxis Ltd Announces New Equity Raising InitiativeDecember 11, 2024 | tipranks.comSyntara Prepares to Unveil Promising Myelofibrosis DataDecember 9, 2024 | tipranks.comPharmaxis Ltd Director Increases Stock OptionsNovember 28, 2024 | tipranks.comPharmaxis Ltd: A Powerhouse of Pharmaceutical ExpertiseNovember 27, 2024 | tipranks.comProactive news headlines including Aurumin, PolarX, Valor Resources and Hartshead ResourcesOctober 5, 2021 | feeds.benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePXSLY and ITRM Company DescriptionsIterum Therapeutics NASDAQ:ITRM$0.03 0.00 (0.00%) As of 05/6/2026Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Pharmaxis OTCMKTS:PXSLY$0.88 0.00 (0.00%) As of 06/8/2021Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
